EORTC abstracts selected at ESMO 2019
18 Sep 2019
In total, EORTC will be presenting 3 abstracts (2 oral presentations and 1 poster) at the ESMO Congress 2019 from 27 September until 1 October in Barcelona, Spain.
Andrew Bottomley, Head of the Quality of Life at EORTC, will chair a session about “Surviving a cancer diagnosis with a good QoL” on 30 September from 8:30 to 10:00 and give a lecture on “Can value frameworks (such as ESMO-MCBS) contribute to a higher QoL?”
During the same session, Madeline Pe, EORTC Specialist in QoL, will talk about EORTC’s work on survivorship.
Meet us at our booth located in the society village n°20.
Oral presentations
A phase II study of Monalizumab in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN): results of the I1 cohort of the EORTC-HNCG-1559 trial (UPSTREAM)
R Galot, C Le Tourneau, E Saada-Bouzid, A Daste, C Even, P Debruyne, S Henry, S Zanetta, A Rutten, L Licitra, JL Canon, MC Kaminsky, P Specenier, S Rottey, L Dirix, T Raveloarivahy, C Fortpied, M Vanlancker, A Govaerts, JP Machiels
Presentation number: 1109O
Speaker: Rachel Galot
Date: 30.09.2019 – Lecture time: 10:15 – 11:45 – Location: Cordoba Auditorium (Hall 7)
Redefining the IGCCCG Classification in advanced Non-Seminoma
Gillessen S, Collette L, Daugaard G, De Wit R, Tryakin A, Albany C, Stahl O, Fizazi K, Gietema J, De Giorgi U, Hansen AR, Feldman D, Cafferty FH, Tandstad T, Garcia del Muro X, Huddart R, Sweeney C, Heng DY, Sauvé N and Beyer J for the IGCCCG Update Consortium
Presentation number: 903O
Speaker: Silke Gillessen
Date: 28.09.2019 – Lecture time: 15:30 – 15:45 – Location: Sevilla Auditorium (Hall 2)
Poster
There is a lack of clinical research for patients with cancer in palliative care
M. Vinches, A. Neven, L. Fenwarth, M. Terada, G. Rossi, S. Kelly, J. Peron, M. Thomaso, M. Groenvold, T. De Rojas
Poster number: 1610P
Poster presenter: Marie Vinches
Date: 28.09.2019 – Lecture time: 12:20 – Location: Poster Area (Hall 4)
Related News
EORTC: Advancing research and treatment for rare cancers
29 Feb 2024
EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration
22 Feb 2024
Appointment of Malte Peters as EORTC Strategic Alliance Officer
9 Feb 2024
Unique series of workshops in partnership with the European Medicines Agency (EMA)
7 Feb 2024
EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)
14 Dec 2023
Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023
6 Dec 2023
EORTC Quality of Life measures integrated in CDISC
20 Nov 2023
EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma
7 Nov 2023
Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia
31 Oct 2023
New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023
20 Oct 2023